The long-term efficacy of targeted therapeutics for cancer treatment can be significantly
limited by the type of therapy and development of drug resistance, inter alia. Experimental …

Combined oncolytic virotherapy and immunotherapy (immunovirotherapy) protocols
represent a promising treatment strategy for a range of cancers and offer many advantages …

Background Immunotherapies, driven by immune-mediated antitumorigenicity, offer the
potential for significant improvements to the treatment of multiple cancer types. Identifying …

Oncolytic virotherapies, including the modified herpes simplex virus talimogene
laherparepvec (T-VEC), have shown great promise as potent instigators of anti-tumour …

V937 is an investigational novel oncolytic non-genetically modified Kuykendall strain of
Coxsackievirus A21 which is in clinical development for the treatment of advanced solid …

Intra-tumour heterogeneity is a leading cause of treatment failure and disease progression
in cancer. While genetic mutations have long been accepted as a primary mechanism of …

We use the McKendrick equation with variable ageing rate and randomly distributed
maturation time to derive a state dependent distributed delay differential equation. We show …

Compartmental ordinary differential equation (ODE) models are used extensively in
mathematical biology. When transit between compartments occurs at a constant rate, the …

The development of new cancer therapies requires multiple rounds of validation from in vitro
and in vivo experiments before they can be considered for clinical trials. Mathematical …

We present a novel mathematical model of heterogeneous cell proliferation where the total
population consists of a subpopulation of slow-proliferating cells and a subpopulation of fast …